Coronary artery disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PCSK9 14
• SGLT2 12
• APOE 0
• GLP-1 4
• NLRP3 2
• PPAR 0
• IL-6 2
• NRF2 0
• CD40 0
• AKT 0
• VEGF 0
• TNF 1
• PI3K 0
• SIRT1 0
• TLR4 0
• TP53 0
• HMGB1 0
• STAT3 0
• HIF-1 0
• AMPK 0
• IL-1 1
• JAK 0
• MMP-9 0
• STING 1
• ACE2 0
• ERK 0
• GIP 1
• mTOR 0
• PD-1 0
• BDNF 0
• COX-2 0
• CXCR4 1
• DPP-4 0
• FGFR 0
• HER2 0
• IL-17 1
• MAPK 0
• PTEN 0
• TREM2 0
• YAP 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APP 0
• BACE1 0
• BCL-2 0
• BRAF 0
• BTK 0
• CCR5 0
• CGRP 0
• CTLA-4 0
• CTNNB1 0
• EZH2 0
• FOXP3 0
• FTO 0
• G6PD 0
• GPX4 0
• HSP90 0
• IL-4 1
• LRRK2 0

24 of 3,057 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, United States· until Oct 2028

• U.S. Department of Veterans Affairs · IK6

  ISRM Research Career Scientist Award Application

  Veterans Health Administration· Pittsburgh, United States· until Sept 2031

• U.S. Department of Veterans Affairs · I01

  Nitrated oleic acid-mediated angiogenesis and long-term functional recovery after ischemic stroke

  Veterans Health Administration· Pittsburgh, United States· until Sept 2030

• NIH NINR · R01

  Discovery of Symptom Burdens and Their Associations with Health Outcomes among People Living with HIV

  University of Texas Hlth Sci Ctr Houston· Houston, United States· US$402,355 awarded in fiscal year 2026· until Jun 2030

• NIH NLM · R21

  MACE-Alert: An Artificial Intelligence based Assessment and Triage of Undifferentiated Chest Pain

  University of California, San Diego· La Jolla, United States· US$216,000 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unmasking the Perivascular Adipose Tissue's Role in Diabetic Vascular Disease From Molecular Clues to Clinical Impact (IMAPERFAT)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €236,340· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Delineating and eradicating cardiovascular inflammageing (DEFLAME)

  Technische Universiteit Eindhoven· Eindhoven, Netherlands· EU contribution €2,500,000· until Feb 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Predicting Female-Predominant Cardiovascular Dissections via multi-scale Hormonal, Imaging, and Biomechanical Integration (DISSEX)

  Aarhus Universitet· Aarhus C, Denmark· EU contribution €1,499,585· until Feb 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DEVELOPMENT OF A NANOHYBRID SYSTEM BASED WEARABLE MICROFLUIDIC PHOTOELECTROCHEMICAL SENSOR FOR THE ON-DEMAND cTnI DETECTION (NANOPEC)

  Kauno Technologijos Universitetas· Kaunas, Lithuania· EU contribution €196,976· until Jan 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Socio-Environmental Determinants of Health in Small States (SEEDS)

  Universita Ta Malta· Msida, Malta· EU contribution €205,314· until Jan 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 2,033 running projects, newest first. Listed amounts together: US$1.2bn + €236.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Everolimus-eluting Stents

  NCT06718179· Odense University Hospital· Updated 22 Oct 2026

  “Insufficient drug supply (prasugrel)”Registry text, quoted unchanged. Source

• Suspended

  Is Our Microbiome a Predictor of Cardiac Risk

  NCT02013284· Mayo Clinic· Updated 20 Oct 2026

  “Reorganizing study personnel and funding”Registry text, quoted unchanged. Source

• Terminated

  Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Heart Disease

  NCT05147766· The Foundation for Orthopaedics and Regenerative Medicine· Updated 20 Oct 2026

  “Inadequate treatment response observed in preliminary data did not justify enrolling further study participants”Registry text, quoted unchanged. Source

• Withdrawn

  3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Stents in NSTE/ACS

  NCT06409117· Konstantinos Toutouzas· Updated 19 Oct 2026

  “No funding”Registry text, quoted unchanged. Source

• Withdrawn

  Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

  NCT07625306· Novartis Pharmaceuticals· Updated 14 Oct 2026

  “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”Registry text, quoted unchanged. Source

• Suspended

  IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

  NCT06071702· Medinol Ltd.· Updated 9 Oct 2026

  “Study was not initiated in any site. Sponsor decided not to start the study”Registry text, quoted unchanged. Source

• Suspended

  Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)

  NCT07449325· VahatiCor, Inc.· Updated 25 Sept 2026

  “Study suspended to implement a protocol change”Registry text, quoted unchanged. Source

• Terminated

  YN001-004 in Patients With Coronary Atherosclerosis in Australia

  NCT06700720· Beijing Inno Medicine Co., Ltd.· Updated 23 Sept 2026

  “The study was terminated at the request of the Sponsor.”Registry text, quoted unchanged. Source

• Withdrawn

  Clinical and Biochemical Effects of a Defined Plant-Based Diet on Heart Disease

  NCT06994624· Georgia State University· Updated 2 Sept 2026

  “Death of lead PI”Registry text, quoted unchanged. Source

• Withdrawn

  Comparative Outcomes of Mammary Artery Harvesting: Infection, Occlusion Rates and Thoracic Pain Assessment

  NCT07720661· Hamilton Health Sciences Corporation· Updated 28 Jul 2026

  “Registered too early. Completing the vanguard first which is registered separately.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Aerobic Exercise-induced Effect on Cardiorespiratory Fitness, Endothelial Function, and Brain-derived Neurotrophic Factor in Patients With Ischaemic Heart Disease

  NCT06788275· Instituto de Investigación Sanitaria y Biomédica de Alicante· Source

• Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

  NCT06678074· Implicit Bioscience· Source

• Health Coaching for Patients With Cardiovascular Disease

  NCT06904144· Ohio State University· Source

• Optical Coherence Tomography in Acute Vessel Evaluation

  NCT07422688· Aarhus University Hospital Skejby· Source

• Bogalusa Heart Study

  NCT00005129· Tulane University· Source

• A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

  NCT07839936· Verve Therapeutics, Inc.· Source

• EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

  NCT05284747· Amgen· Source

• Effect of the SCOT-HEART 2 Trial on Lifestyle.

  NCT04156061· University of Edinburgh· Source

• Telegram Messenger Support for Smoking Cessation After Heart Attack

  NCT07230249· ITMO University· Source

• ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY

  NCT07545512· University Hospital, Clermont-Ferrand· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 14
• Organoids 1
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 4
• Gene Expression Profiling 48
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 6
• Proteomics 68
• Metabolomics 41
• Mass Spectrometry 5
• Flow Cytometry 26
• Immunohistochemistry 12
• Positron-Emission Tomography 64
• Magnetic Resonance Imaging 66
• Machine Learning 163
• Deep Learning 85
• Cohort Studies 405
• Genome-Wide Association Study 163

• Genotype-first approach reveals monogenic lipodystrophy is underdiagnosed, with health and mortality risks.

  EBioMedicine, Apr 2026

See which targets of this disease your abstract mentions, and go to the people working on them.